-
Access to AlloTx for AML: the value of the social phenotype. Blood (IF 21.0) Pub Date : 2025-06-19 Gary Schiller
-
Disrupting HIT immune complexes as a new treatment for HIT. Blood (IF 21.0) Pub Date : 2025-06-19 Beng H Chong
-
-
-
Severe oxidant hemolysis in a child with G6PD deficiency and Hb C trait. Blood (IF 21.0) Pub Date : 2025-06-19 Connor Cocke,Weijie Li
-
A natural head start to MRD negativity in multiple myeloma. Blood (IF 21.0) Pub Date : 2025-06-19 Erin W Meermeier
-
-
Precision pre-HSCT conditioning by targeting cMPL. Blood (IF 21.0) Pub Date : 2025-06-19 Markus G Manz
-
High-Dose Busulfan-Melphalan vs. Melphalan and Reinforced VRD in Newly Diagnosed Multiple Myeloma. A Phase III GEM Trial Blood (IF 21.0) Pub Date : 2025-06-14 Juan José Lahuerta PhD, Jesús San-Miguel PhD, Ana Jiménez-Ubieto PhD, Rafael Alonso MD, Bruno Paiva PhD, Noemí Puig PhD, M. Teresa Cedena PhD, Norma Carmen Gutierrez PhD, María José Calasanz PhD, Manuela Fernández-Guijarro MSc, Rafael Ríos Tamayo PhD, Albert Oriol Rocafiguera MD, María Jesús Blanchard MD, Estrella Carrillo MD, Rafael Martínez-Martínez MD, Joan Bargay PhD, Ana Sureda-Balari PhD, Javier
In retrospective studies, autologous stem cell transplantation (ASCT) conditioning with intravenous busulfan and melphalan (BUMEL) led to longer progression-free survival (PFS) than melphalan alone (MEL200). We compared BUMEL vs. MEL200 outcomes in newly diagnosed multiple myeloma (NDMM) patients receiving intensified bortezomib, lenalidomide and dexamethasone (VRD) induction and consolidation therapy
-
TNFα signaling restores steady-state hematopoiesis in a TNFαKO mouse model of anemia of inflammation. Blood (IF 21.0) Pub Date : 2025-06-13 Amaliris Guerra,Vania Lo Presti,Ding-Wen Chen,Ana C Martins,Ariel Rivera,Nolan Hamilton,Pankaj Sharma,Yelena Z Ginzburg,Carlo Castruccio Castracani,Carla Casu,Ritama Gupta,Raffaella Gozzelino,Edward M Behrens,Laura Bennett,Robert F Paulson,Peter Kurre,Stefano Rivella
Anemia of inflammation (AI) is the second most common form of anemia and is prevalent in patients with chronic inflammatory states, such as infection, autoimmunity, and cancer. Interleukin 6 (IL6) is well-known to induce the iron-sequestering hormone hepcidin, which results in iron-restricted anemia. The contributions of other pro-inflammatory cytokines such as tumor necrosis factor-α (TNFα) and interferon-γ
-
Array Genotyping of Transfusion Relevant Blood Cell Antigens in 6946 Ancestrally Diverse Subjects Blood (IF 21.0) Pub Date : 2025-06-13 Nicholas S. Gleadall, Lianne Koets, Olga Shamardina, Jeremy Gollub, Aaron J. Gottschalk, Orod Razeghi, Gorka Ochoa-Garay, Jonathan Stephens, Ram Varma, Jennifer Martin, Elias Allara, Colin J. Brown, James Daly, Emanuele Di Angelantonio, Shane Grimsley, W. Martin Howell, Kati Hyvärinen, Ute Jentsch, Nathalie Kingston, Celina Montemayor, Celeste Moya-Valera, John Ord, Jukka Partanen, David Roberts, Kathleen
Blood transfusions save millions of lives worldwide each year, yet formation of antibodies against non-self antigens remains a significant problem, particularly in frequently transfused patients. We designed and tested the Universal Blood Donor Typing (UBDT_PC1) array for automated high-throughput simultaneous typing of human erythroid, platelet, leukocyte, and neutrophil antigens (HEA, HPA, HLA, and
-
Correlates and Consequences of Clonal Hematopoiesis Expansion Rate: A 16-Year Longitudinal Study of 6,976 Women Blood (IF 21.0) Pub Date : 2025-06-13 Yash Pershad, Md Mesbah Uddin, Liying Xue, Jeffrey Haessler, Jason M. Collins, Taralynn M. Mack, Elena Glick, Veronica Glaser, Kun Zhao, Siddhartha Jaiswal, JoAnn E. Manson, Urvashi Pandey, Pinkal Desai, Pradeep Natarajan, Michael C. Honigberg, Charles Kooperberg, Eric A. Whitsel, Jacob O. Kitzman, Alexander G. Bick, Alexander P. Reiner
Clonal hematopoiesis of indeterminate potential (CHIP) is associated with increased mortality and malignancy risk, yet the determinants of clonal expansion remain poorly understood. We performed sequencing at >4,000x depth of coverage for CHIP mutations in 6,976 postmenopausal women from the Women's Health Initiative at two timepoints: the WHI baseline exam and approximately 16 years later at the Long
-
Combined PET and ctDNA response as predictors of POD24 for follicular lymphoma after first-line induction treatment. Blood (IF 21.0) Pub Date : 2025-06-13 Alexis Claudel, Anne Ségolène Cottereau, Emmanuel Bachy, Emmanuel Itti, Pierre Feugier, Cedric Rossi, Francois Lemonnier, Vincent Camus, Nicolas Daguindau, Guillaume Cartron, Emmanuelle Nicolas-Virelizier, Diana-Laure MBoumba, Christophe Cardoso, Côme Bommier, Benoit Tessoulin, Christophe Fruchart, Adrien Gilbert, Eric Durot, Emmanuel Fleck, Gian Matteo Pica, Hacene Zerazhi, Stephanie Guidez, Morgane
Patients with follicular lymphoma (FL) who experience disease progression within 24 months of diagnosis (POD24) have a lower survival. Positron emission tomography (PET) response and circulating tumor DNA (ctDNA) residual disease (MRD) assessment at end of induction therapy (EOI) may allow their early identification. A representative cohort of 141 patients from the RELEVANCE phase III trial with both
-
Remission conversion drives outcomes after CAR T-cell therapy for multiple myeloma: a registry analysis from the DRST. Blood (IF 21.0) Pub Date : 2025-06-12 Maximilian Merz,Nico Gagelmann,Samih Smaili,Sarah Flossdorf,Sandra Sauer,Christof Scheid,Bastian von Tresckow,Gerald Georg Wulf,Katja C Weisel,Igor Blau,Monika Engelhardt,Ralph Wäsch,Natalie Schub,Raphael Teipel,Judith S Hecker,Johannes M Waldschmidt,Britta Besemer,Ben-Niklas Baermann,Simon Call,Leo Hansmann,Francis Ayuketang Ayuk,Marc S Raab,Hermann Einsele,Uwe Platzbecker,Nicolaus Kröger
Cellular therapies targeting B-cell maturation antigen have shown promise in controlled clinical trials, but their impact in broader, diverse patient populations remains underexplored. This study examines the real-world efficacy and safety in 343 triple-class exposed patients with relapsed and refractory multiple myeloma (RRMM) who received idecabtagene vicleucel (ide-cel, n=266) or ciltacabtagene
-
A single dose of a CD137 antibody-drug conjugate protects nonhuman primate allogeneic HCT recipients against acute GVHD. Blood (IF 21.0) Pub Date : 2025-06-12 Ulrike Gerdemann,Kyle Kimler,Matthew R Warren,Connor McGuckin,Ryan A Fleming,Matthew R D'Ambra,Alal Eran,Alexandre Albanese,Edward Chen,Marlana B Winschel,Lorenzo Cagnin,Jennifer Lane,Lev Gorfinkel,Bartley W Adams,Jean Kwun,Leanne Lanieri,Megan D Hoban,Tahirih L Lamothe,Sharon L Hyzy,Lisa M Olson,Angela Panoskaltsis-Mortari,Susan E Prockop,Bruce R Blazar,Leslie S Kean,Victor Tkachev
Rapid CD137 upregulation on alloreactive T-cells upon allogeneic stimulation suggests that their selective elimination could prevent acute graft-versus-host disease (aGVHD) after allogeneic hematopoietic stem cell transplantation (HCT). Here, we developed a novel aGVHD prophylactic regimen consisting of a single dose of an anti-CD137 antibody-drug conjugate (CD137-ADC) administered on the day of transplant
-
Comparison of the safety profiles of CD19-targeting CAR T-cell therapy in patients with SLE and B-cell lymphoma. Blood (IF 21.0) Pub Date : 2025-06-12 Fabian Müller,Nora Rebecca Schwingen,Melanie Hagen,Julia Katharina Scholz,Michael Aigner,Andreas Wirsching,Jule Taubmann,Sascha Kretschmann,Soraya Kharboutli,Tobias Krickau,Nora Naumann-Bartsch,Giulia Benintende,Silvia Spoerl,Tobias Rothe,Heiko Bruns,Ricardo Grieshaber-Bouyer,Markus Metzler,David B Blumenthal,Frederik Graw,Georg Schett,Andreas Mackensen,Simon Völkl
CD19-directed chimeric antigen receptor (CAR) T-cell therapy has revolutionized the treatment of relapsed/refractory B-cell non-Hodgkin lymphoma (B-NHL) and recently showed effects in autoimmune diseases such as systemic lupus erythematosus (SLE). Despite high levels of inflammation, toxicity appeared to differ in SLE and B-NHL. We therefore compared CAR T-cell kinetics and treatment-related side-effects
-
RhoA GAP Myo9b regulates β2-integrin activity and neutrophil recruitment during murine acute kidney injury. Blood (IF 21.0) Pub Date : 2025-06-12 Anika Cappenberg,Marina Oguama,Mathis Richter,Andreas Margraf,Wida Amini,Pia Lindental,Sina Mersmann,Bernadette Bardel,Helena Block,Thomas Vogl,Oliver Soehnlein,Klaus Ley,Jan Rossaint,Alexander Zarbock
An acute inflammatory response to infection or sterile injury involves an adequate activation and recruitment of leukocytes. Activation of β2-integrins is required for neutrophil recruitment and is also mandatory for various neutrophil cell-intrinsic functions. GTPases are key regulators of the actin cytoskeleton and are required for β2-integrin activation. MyosinIXb (Myo9b), a Rho GTPase-activating
-
-
-
-
Introduction to a Blood Spotlight series on acute myeloid leukemia Blood (IF 21.0) Pub Date : 2025-06-12 Selina M. Luger
-
-
-
Rilzabrutinib, the first-in-class BTK inhibitor for ITP Blood (IF 21.0) Pub Date : 2025-06-12 Marc Michel
-
Predicting T-ALL response to pre-TCR and IL-7R coinhibition Blood (IF 21.0) Pub Date : 2025-06-12 Carol Fries
-
Chronic GVHD: one more promising player enters the arena Blood (IF 21.0) Pub Date : 2025-06-12 Francis A. Ayuk
-
A small B-cell leukemia/lymphoma with weak to negative expression of CD5 Blood (IF 21.0) Pub Date : 2025-06-12 Shamini Selvarajah, Daniel Xia
-
TET3 stirs up trouble via pathogenic Ig class switching Blood (IF 21.0) Pub Date : 2025-06-12 Daigo Hashimoto
-
Challenges in GvHD and GvL after hematopoietic stem cell transplantation for myeloid malignancies Blood (IF 21.0) Pub Date : 2025-06-11 Gerard SOCIE MD PhD
Although allogeneic HCT is a leading treatment approach for myeloid malignancies, challenges in its immune biology and in treatment approaches remain. In the past decade major advances in the knowledge of mechanisms of graft-versus host disease (GvHD) has allowed development of new treatments both for GvHD prophylaxis and treatment. However, although successes did occur, failure did as well. Reasons
-
Eliminating The Need for Sequential Confirmation of Response in Multiple Myeloma Blood (IF 21.0) Pub Date : 2025-06-11 Jean-Sébastien Claveau, Prashant Kapoor, Moritz Binder, Francis Buadi, David Dingli, Angela Dispenzieri, Amie Fonder, Morie Gertz, Wilson Gonsalves, Suzanne Hayman, Miriam Hobbs, Yi Lisa Hwa Christenson, Taxiarchis Kourelis, Martha Lacy, Nelson Leung, Yi Lin, Rahma Warsame, Robert Kyle, Vincent Rajkumar, Shaji K Kumar
Disease response and progression assessment in multiple myeloma (MM) is based on various measurements of monoclonal protein (serum and urine protein electrophoresis, serum free light chain (FLC, and or quantitative immunoglobulins). Currently, the IMWG consensus response criteria require two sequential assessments of any one marker made at any time before confirmation of disease progression and the
-
Single-cell and clonal analysis of AL amyloidosis plasma cells and their bone marrow microenvironment. Blood (IF 21.0) Pub Date : 2025-06-10 Nicolas A Gort-Freitas,Maria Moscvin,Matteo Claudio Da Viá,Francesca Lazzaroni,Alice Nevone,Sam Sadigh,Samuel Boullt,Benjamin Evans,Tianzeng Chen,Tanya T Karagiannis,Albert Tai,Sean Rowell,Srinidhi Raghav,Antonia Faustina Chen,Jacob P Laubach,Caitlin Edwards,Jon C Aster,Zizhang Sheng,Joao A Paulo,Chi N Chan,Mario Nuvolone,Niccolò Bolli,Raymond L Comenzo,Allon Klein,Giada Bianchi
AL amyloidosis is a disorder characterized by expansion of clonal plasma cells in the bone marrow and distant end organ damage mediated by misfolded immunoglobulin free light chains. There are currently limited data regarding the functional characteristics of AL amyloidosis plasma cells and their surrounding bone marrow microenvironment. We performed 5' single cell RNA sequencing on newly diagnosed
-
Biallelic antigen escape is a mechanism of resistance to anti-CD38 antibodies in multiple myeloma. Blood (IF 21.0) Pub Date : 2025-06-10 Benjamin T Diamond,Linda B Baughn,Mansour Poorebrahim,Alexandra M Poos,Holly Lee,Marcella Kaddoura,J Erin Wiedmeier-Nutor,Michael A Durante,Gregory E Otteson,Dragan Jevremovic,Hongwei Tang,Stefan Fröhling,Marc-Andrea Baertsch,Marios Papadimitriou,Bachisio Ziccheddu,Tomas Jelínek,Cendrine Lemoine,Alexey Rak,Damian J Green,Carl Ola Landgren,Paola Neri,Peter Leif Bergsagel,Esteban Braggio,Shaji K Kumar
Monoclonal antibodies targeting CD38 are a therapeutic mainstay in multiple myeloma (MM). While they have contributed to improved outcomes, most patients still experience disease relapse, and little is known about tumor-intrinsic mechanisms of resistance to these drugs. Antigen escape has been implicated as a mechanism of tumor cell evasion in immunotherapy. Yet, it is unknown whether MM cells can
-
An in vivo barcoded CRISPR-Cas9 screen identifies Ncoa4-mediated ferritinophagy as a dependence in Tet2-deficient hematopoiesis. Blood (IF 21.0) Pub Date : 2025-06-10 Justin Loke,Peter Geon Kim,Thuy T P Nguyen,Meaghan Boileau,Marie McConkey,Aidan P Miller,Wesley Shin,Christopher B Hergott,Maria Ericsson,Anja Nordstrom,Paula Montero-Llopis,Scott A Armstrong,Joseph D Mancias,Benjamin L Ebert
TET2 is among the most commonly mutated genes in both clonal hematopoiesis and myeloid malignancies, thus, the ability to identify selective dependencies in TET2 deficient cells has broad translational significance. Here, we identify regulators of Tet2 knockout (KO) hematopoietic stem and progenitor cell (HSPC) expansion using an in vivo CRISPR-Cas9 KO screen, in which nucleotide barcoding enabled
-
The T follicular helper/T follicular helper regulatory pathway in FVIII immune responses in mice. Blood (IF 21.0) Pub Date : 2025-06-10 Weiqing Jing,Jocelyn A Schroeder,Saurabh Kumar,Juan Chen,Yuanhua Cai,Lynn M Malec,Alexander L Dent,Weiguo Cui,Qizhen Shi
Developing anti-FVIII inhibitory antibodies (inhibitors) is a significant complication of FVIII protein replacement therapy in hemophilia A. Our previous study demonstrated that follicular helper T (TFH) cells play a critical role in FVIII inhibitor development. Follicular regulatory T (TFR) cells are a subset of Foxp3+ T cells recently identified in the germinal center that can modulate TFH cell activation
-
The sweet business of VWF clearance. Blood (IF 21.0) Pub Date : 2025-06-05 Renhao Li,Robert F Sidonio
-
MURANO's final conclusions: what we've learned, what's next? Blood (IF 21.0) Pub Date : 2025-06-05 Othman Al-Sawaf
-
Exploiting tumor-derived IL-10 activity in lymphoma therapy. Blood (IF 21.0) Pub Date : 2025-06-05 Reuben Tooze,Ulf Klein
-
Burkitt lymphoma: click here to add to CAR-T? Blood (IF 21.0) Pub Date : 2025-06-05 Eliza A Hawkes,Gareth P Gregory
-
The advent of multiomics in experimental transplantation. Blood (IF 21.0) Pub Date : 2025-06-05 Gerard Socie
-
-
Getting to the root of high-risk leukemias. Blood (IF 21.0) Pub Date : 2025-06-05 Michael Poeschla,Vijay G Sankaran
-
Classic Hodgkin lymphoma in the cerebellum: a rare site for a common disease. Blood (IF 21.0) Pub Date : 2025-06-05 Yukiko Kitagawa,Elaine S Jaffe
-
Reactivation of developmentally silenced globin genes through forced linear recruitment of remote enhancers Blood (IF 21.0) Pub Date : 2025-06-04 Anna-Karina Felder, Sjoerd J. D. Tjalsma, Han J. M. P. Verhagen, Rezin Majied, Marjon J. A. M. Verstegen, Thijs C. J. Verheul, Jeffrey van Haren, Rebecca Mohnani, Richard Gremmen, Peter H. L. Krijger, Sjaak Philipsen, Emile van den Akker, Wouter de Laat
The human genome contains regulatory DNA elements, known as enhancers, that can activate gene transcription over long chromosomal distances. Here, we showed that enhancer distance can be critical for gene silencing. We demonstrated that linear recruitment of the normally distal strong HBB enhancer to developmentally silenced embryonic HBE or fetal HBG promoters through deletion or inversion of intervening
-
Hitting the therapeutic bull’s-eye with targeted therapy for patients with chronic lymphocytic leukemia Blood (IF 21.0) Pub Date : 2025-06-04 William G. Wierda, Barbara Eichhorst, Michael Hallek
Chronic lymphocytic leukemia (CLL) is a disease of great clinical and biologic heterogeneity; some patients are observed for years without symptoms, whereas others rapidly develop progressive disease requiring treatment. With therapy, some patients eventually develop resistant CLL or transformation to an aggressive form. Across this spectrum, patients experience immune dysfunction associated with increased
-
Phase 1/2 trial of anti-CD7 allogeneic WU-CART-007 for patients with relapsed/refractory T-cell malignancies Blood (IF 21.0) Pub Date : 2025-06-02 Armin Ghobadi, Ibrahim Aldoss, Shannon L. Maude, Deepa Bhojwani, Alan S. Wayne, Ashish Bajel, Bhagirathbhai Dholaria, Rawan Faramand, Ryan J. Mattison, Anita Rijneveld, C. Michel Zwaan, Friso Calkoen, Andre Baruchel, Nicolas Boissel, Michael Rettig, Brent Wood, Kenneth Jacobs, Stephanie Christ, Haley Irons, Ben Capoccia, Deborah Masters, Justo Gonzalez, Tony Wu, Maria del Rosario, Alexander Hamil,
Relapsed/refractory T-cell acute lymphoblastic leukemia (ALL; T-ALL)/lymphoma (LBL) represent a significant unmet medical need. WU-CART-007 is a CD7-targeting, allogeneic, fratricide-resistant chimeric antigen receptor T-cell product generated from healthy donor T cells. WU-CART-007 was evaluated in a phase 1/2 study with a 3+3 dose-escalation design followed by cohort expansion in relapsed/refractory
-
PERK signaling maintains hematopoietic stem cell pool integrity under endoplasmic reticulum stress by promoting proliferation Blood (IF 21.0) Pub Date : 2025-05-30 Manxi Zheng, Qinlu Peng, Erin M. Kropp, Zhejuan Shen, Suxuan Liu, Zhengyou Yin, Sho Matono, Takao Iwawaki, Xiang Wang, Ken Inoki, Yang Mei, Qing Li, Lu Liu
The integrity of the hematopoietic stem cell (HSC) pool depends on effective long-term self-renewal and the timely elimination of damaged or differentiation-prone HSCs. Although the protein kinase R–like endoplasmic reticulum kinase (PERK) branch of the unfolded protein response has been shown to initiate proapoptotic signaling in response to endoplasmic reticulum (ER) stress in vitro, its role in
-
I+Ve got a question: how long should we treat relapsed CLL? Blood (IF 21.0) Pub Date : 2025-05-29 Moritz Fürstenau
-
It's high TIM-3 for armored CAR-T therapy for B-ALL. Blood (IF 21.0) Pub Date : 2025-05-29 Alexandros Rampotas,Claire Roddie
-
Are you ready for it? VEN-HMA for younger patients with AML. Blood (IF 21.0) Pub Date : 2025-05-29 Tara L Lin
-
HLA antibodies delay platelet recovery after gene therapy. Blood (IF 21.0) Pub Date : 2025-05-29 Ashish O Gupta,Akshay Sharma
-
Guidance on the interpretation of CRBN mutations in myeloma. Blood (IF 21.0) Pub Date : 2025-05-29 K Martin Kortüm,Hermann Einsele
-
Primary myelofibrosis involving lymph nodes with the same mutational profile in bone marrow. Blood (IF 21.0) Pub Date : 2025-05-29 Yanna Ding,Kikkeri N Naresh
-
Unveiling the enigma: circulating flowerlike large B-lymphoma cells in the context of angioimmunoblastic T-cell lymphoma. Blood (IF 21.0) Pub Date : 2025-05-29 Bhaumik Shah,Reza Nejati
-
RBM15-MKL1 fusion protein promotes leukemia via m6A methylation and WNT pathway activation Blood (IF 21.0) Pub Date : 2025-05-26 Madeline Y. Mayday, Giulia Biancon, Manyi Wei, Christian Ramirez, Irene Moratti, Andreas P. Pintado-Urbanc, Jether Amos Espinosa, Mi Chen, Lin Wang, Matthew D. Simon, Yaara Ofir-Rosenfeld, Oliver Rausch, Toma Tebaldi, Stephanie Halene, Diane S. Krause
Acute megakaryoblastic leukemia (AMKL) that is driven by the RBM15-MKL1 fusion protein (RM-AMKL) is encoded by the recurrent t(1;22) translocation. Dysregulation of the N6-methyladenosine (m6A) modification affects RNA fate and is linked to oncogenesis. Because RBM15 is critical for bringing the m6A writer complex to specific RNAs, we hypothesized that RM disrupts the m6A modification, thereby altering
-
Ultrasensitive detection of circulating multiple myeloma cells by next-generation flow after immunomagnetic enrichment Blood (IF 21.0) Pub Date : 2025-05-26 Marta Lasa, Carmen Gonzalez, Laura Notarfranchi, Anastasiia Zherniakova, Diego Alignani, Leire Burgos, Maria Jose Calasanz, Paula Rodriguez-Otero, Jose J. Perez, Clara Gomez, Veronica Gonzalez de la Calle, Felipe de Arriba, Luis Palomera, Miguel Angel Alvarez Rivas, Esther Clavero, Enrique M. Ocio, Ana Pilar Gonzalez-Rodriguez, Sunil Lakhwani, Angela Ibañez, Albert Oriol, Anna Sureda, Laura Rosiñol
The continuous improvement in progression-free survival (PFS) of patients with multiple myeloma (MM) raises interest in evaluating peripheral residual disease (PRD) toward more frequent readouts of tumor kinetics while preserving quality of life. Here, we present BloodFlow, a new method that combines immunomagnetic enrichment of CD138+ circulating plasma cells in peripheral blood (PB) with next-generation
-
Type 2 calreticulin mutations activate ATF6 to promote BCL-xL–mediated survival in myeloproliferative neoplasms Blood (IF 21.0) Pub Date : 2025-05-26 Nicole S. Arellano, William L. Heaton, Mirielle C. Nauman, Abigail E. Runnels, Jacky Gomez-Villa, Daniele Vanni, Melissa Gaviria, Maihi Fujita, Nathan M. Krah, Michele Ciboddo, Saveg Yadav, Callie T. Brown, Parker D. Bowden, Amy K. Chen, Christopher Henning, Silvia Catricalà, Ilaria Carola Casetti, Oscar Borsani, Elisa Rumi, Daniela Pietra, Isabelle Plo, Caroline Marty, Marco Marchetti, Ami B. Patel
Most calreticulin (CALR) mutations in myeloproliferative neoplasms are classified as either type 1, a 52–base pair deletion (CALRdel52); or type 2, a 5–base pair insertion (CALRins5). Both are gain-of-function (GOF) mutations that generate an identical mutant C-terminal tail, which mediates the binding to, and activation of, the thrombopoietin receptor myeloproliferative leukemia protein (MPL). We
-
Plasminogen activation and plasmin activity are not required to prevent venous thrombosis/thromboembolism Blood (IF 21.0) Pub Date : 2025-05-26 Yaqiu Sang, Marzia Menegatti, Jennifer A. Brody, Kerri L. Wiggins, Brian C. Cooley, Katheryn N. Kapfer, Kadri Kangro, Bas de Laat, Flora Peyvandi, Matthew J. Flick, Nicholas L. Smith, Amy D. Shapiro, Alisa S. Wolberg
Suppression of plasminogen activation and/or plasmin activity (PA) reduces blood loss and decreases hemorrhage-related death. However, whether the endogenous PA system is a biological mechanism to prevent intravascular thrombus formation is debated, and the potential that reduced PA may increase venous thrombosis/thromboembolism (VTE) risk cautions against the use of antifibrinolytic agents. We aimed
-
Sequential combinations of rapid immunoassays for prompt recognition of heparin-induced thrombocytopenia Blood (IF 21.0) Pub Date : 2025-05-26 Thomas Steinauer, Elena Matthey-Guirao, Francisco J. Gomez, Luana Rittener-Ruff, Matteo Marchetti, Matthew Goodyer, Mitja Nabergoj, Stefano Barelli, Francesco Grandoni, Maxime G. Zermatten, Lorenzo Alberio
Early recognition and treatment of heparin-induced thrombocytopenia (HIT) are crucial to prevent severe complications. Although immunoassays offer rapid diagnosis, their sensitivity and specificity are suboptimal. Sequential combinations of quantitative immunoassay results improve their diagnostic accuracy. We aimed to validate 2 Bayesian approaches combining 2 rapid immunoassays and to compare their
-
CRISPR-Cas13d functional transcriptomics reveals widespread isoform-selective cancer dependencies on lncRNAs Blood (IF 21.0) Pub Date : 2025-05-26 Eugenio Morelli, Anil Aktas-Samur, Domenico Maisano, Claire Gao, Vanessa Favasuli, Dimitrios Papaioannou, Giovanni De Nola, Jon E. Henninger, Na Liu, Marcello Turi, Pietro Folino, Laure Vreux, Michela Cumerlato, Liang Chen, Iannis Aifantis, Mariateresa Fulciniti, Kenneth C. Anderson, Abigail K. R. Lytton-Jean, Annamaria Gullà, Richard A. Young, Mehmet K. Samur, Nikhil C. Munshi
Long noncoding RNAs (lncRNAs) are a significant yet largely uncharted component of the cancer transcriptome, with their isoform-specific functions remaining poorly understood. In this study, we used RNA-targeting CRISPR-Cas13d to uncover and characterize hundreds of tumor-essential lncRNA (te-lncRNA) isoforms with clinical relevance. Focusing on multiple myeloma (MM), we targeted the lncRNA transcriptome
-
Imaging mass cytometry reveals the order of events in the pathogenesis of immune-mediated aplastic anemia Blood (IF 21.0) Pub Date : 2025-05-26 Emma S. Pool, Sietse J. Luk, Marieke E. IJsselsteijn, Vincent van Unen, Noel F. C. C. de Miranda, J. H. Frederik Falkenburg, Frits Koning, Mirjam H. M. Heemskerk, Jennifer M.-L. Tjon
The autoimmune response driving hematopoietic stem and progenitor cell (HSPC) destruction in immune-mediated aplastic anemia (AA) remains incompletely understood. We previously identified a disease-specific immune cell network involving T, B, and myeloid cells. However, the interactions within this network, the interaction with the microenvironment, and the chronological events in AA development, remain